Sprotte 25G needle, stylet reinserted
DeviceLumbar puncture with small bore atraumatic needle, stylet reinserted before needle withdrawal
NCT Number: NCT03960749
The objectives of this study are to investigate the effects of needle design, needle size and stylet reinsertion on the risk for headache after diagnostic LP (lumbar puncture, Post-LP headache). The following needles are used in the study:
1. Sprotte 25 Gauge (G) (0.5 mm) atraumatic needle with introducer 2. Sprotte 22 G (0.7 mm) atraumatic needle with introducer 3. Spinocan 25 G (0.5 mm) cutting needle
Looking for future studies?
Notify Me16 year and older
All sexes
Interventional
Not applicable
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-Subjects unable to participate in the study follow-up
Lumbar puncture with small bore atraumatic needle, stylet reinserted before needle withdrawal
Lumbar puncture with small bore atraumatic needle, stylet not reinserted before needle withdrawal
Lumbar puncture with larger bore atraumatic needle, stylet reinserted before needle withdrawal
Lumbar puncture with larger bore atraumatic needle, stylet not reinserted before needle withdrawal
Lumbar puncture with small bore cutting needle, stylet reinserted before needle withdrawal
Lumbar puncture with small bore cutting needle, stylet not reinserted before needle withdrawal
Time frame: Up to 14 days after LP
Any post-lumbar puncture headache (as defined in the international classification of headache disorders 3 (ICHD-3).
Time frame: Up to 14 days after LP
Severe (preventing daily activities) post-lumbar puncture headache (as defined in the international classification of headache disorders 3 (ICHD-3).
Time frame: Until cessation, up to 14 days after LP
Time frame: During post-lumbar puncture headache, up to 14 days after LP
Time frame: During post-lumbar puncture headache, up to 14 days after LP
Time frame: Up to 14 days after LP
Time frame: Up to 14 days after LP
Time frame: Up to 14 days after LP
Interactions between important predictors of headache and needle allocation, assessed in multivariable logistic regression models with interaction terms which are the products of the two potentially interacting variables. Age and BMI will be treated as continuous variables, sex and needle allocation as categorical variables.
Time frame: During the lumbar puncture
Procedure duration from start of procedure (defined as when the operator starts palpating the iliac crest) until procedure cessation (defined as when the needle is withdrawn from the participant).
Time frame: During the lumbar puncture
Technical difficulties may differ between needles and thus the proportion undergoing needle switch due to these difficulties may differ.
Time frame: During the lumbar puncture
Opening pressure measured immediately after cerebrospinal fluid (CSF) contact using a thin tube attached to a paper ruler, using the skin entry hole as reference point. This is only performed in the recumbent position.
Jonatan Salzer
Other Gov
The Importance of Needle Size, Needle Design and Stylet Reinsertion to Prevent Post-lumbar Puncture Headache, a Randomized Controlled Trial
Acronym: HELPUmeå
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01977898
Brain Diseases, Central Nervous System Diseases
Chicago, Illinois, United States
View Trial DetailsNCT06062446
Brain Diseases, Central Nervous System Diseases
Houston, Texas, United States
View Trial DetailsNCT01481922
Back Pain, Backache
Montreal, Quebec, Canada
View Trial DetailsNCT06805591
Brain Diseases, Central Nervous System Diseases
Glostrup Municipality, Copenhagen, Denmark
View Trial Details